8-K: NeurAxis Appoints Timothy Henrichs as Chief Financial Officer Following Board Resignation

NeurAxis, Inc. has appointed Timothy Henrichs as its new Chief Financial Officer, effective February 5, 2024, following his resignation from the Board of Directors.

Summary

• NeurAxis, Inc. announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024.
• This appointment follows Mr. Henrichs' resignation from the Board of Directors, effective February 2, 2024.
• The previous CFO, John Seale, resigned on January 30, 2024.
• Mr. Henrichs will receive an annual base salary of $330,000, health insurance premiums, and paid personal time off.
• He will also receive 100,000 shares of common stock as an inducement to join the company.
• Mr. Henrichs previously served on the Board since August 8, 2023, and was paid $8,790 for his services as a non-employee director in 2023.
• He is also owed approximately $20,000 in unpaid cash fees and shares valued at approximately $23,700 for his prior service as a non-employee director.
• Mr. Henrichs has over 17 years of experience as a finance executive across various industries, including healthcare, home improvement, retail, software, and education.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the appointment of an experienced CFO, but there are some concerns about the recent resignations and outstanding payments to the new CFO.

Positives

• The appointment of Timothy Henrichs brings a seasoned finance executive with over 17 years of experience across various industries.
• Mr. Henrichs' experience includes leadership roles at Renovo Home Partners, Follett Corporation, and General Electric's Healthcare division.
• The company is providing an inducement of 100,000 shares of common stock to secure Mr. Henrichs as CFO.

Negatives

• The company has experienced a resignation of both a board member and the CFO within a short period.
• The company owes Mr. Henrichs approximately $20,000 in unpaid cash fees and shares valued at approximately $23,700 for his prior service as a non-employee director.

Risks

• The company is undergoing a transition in key financial leadership roles.
• The company's future performance is subject to various risks and uncertainties, including economic conditions, stock volatility, and clinical trial results.

Future Outlook

The company is moving forward with strategic commercialization activities in 2024 and beyond, with the new CFO playing a key role.

Management Comments

• Brian Carrico, President and Chief Executive Officer of NeurAxis, stated that Mr. Henrichs' extensive experience will be highly valuable as the company continues to move forward with its strategic commercialization activities.
• Tim Henrichs stated that it is an incredible opportunity to join the Company especially at such a pivotal point in its growth and he looks forward to being part of the team and the mission to improve patient outcomes.

Industry Context

The appointment of a new CFO is a common occurrence in the corporate world, especially for companies undergoing growth or strategic changes. The healthcare industry is known for its complex financial landscape, making the CFO role critical.

Comparison to Industry Standards

• The compensation package for the new CFO, including a $330,000 base salary and stock options, is within the typical range for a company of this size and stage in the medical technology sector.
• The appointment of a CFO with experience in healthcare, as well as other industries, is a common practice to bring diverse perspectives to the financial leadership of the company.
• The use of stock options as an inducement is a standard practice to align the CFO's interests with the company's long-term success.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively.
• Employees may experience changes in leadership and financial direction.
• Customers and suppliers may not be directly impacted by this change.

Next Steps

• Mr. Henrichs will begin his employment as CFO on February 5, 2024.
• The company will continue its strategic commercialization activities in 2024 and beyond.

Key Dates

Keywords

Chief Financial Officer, CFO, Timothy Henrichs, Board of Directors, executive appointment, financial leadership, NeurAxis, NRXS